ReviewNature reviews. Clinical oncology2009
Molecular therapy in head and neck oncology.
Review in Nature reviews. Clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 91 citations in OpenAlex.
- CDKN2A, ITGA3, SMAD4 and SIRT7 gene expression in human cutaneous squamous cell carcinoma development and pre-clinical diagnosis.BMC cancer · 2026Article
- Dynamic change of gut microbiota in head and neck concurrent chemoradiotherapy patients and its potential value in the prediction of acute oral mucositis grade as well as quality of life.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Statins block mammalian target of rapamycin pathway: a possible novel therapeutic strategy for inflammatory, malignant and neurodegenerative diseases.Inflammopharmacology · 2023Review
- Emerging roles of protein palmitoylation and its modifying enzymes in cancer cell signal transduction and cancer therapy.International journal of biological sciences · 2022Review
- Tumor microenvironment is not an 'innocent bystander' in the resistance to treatment of head and neck cancers (Review).Experimental and therapeutic medicine · 2021Review
- Dual blockade of EGFR and CDK4/6 delays head and neck squamous cell carcinoma progression by inducing metabolic rewiring.Cancer letters · 2021Article
- Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy.Signal transduction and targeted therapy · 2021Review
- The Prognostic Value and Mechanisms of TMEM16A in Human Cancer.Frontiers in molecular biosciences · 2021Review
- Gene expression analysis of primary gingival cancer by whole exome sequencing in thirteen Chinese patients.International journal of clinical and experimental pathology · 2020Article
- Monitoring the dynamics of hemeoxygenase-1 activation in head and neck cancer cells in real-time using plasmonically enhanced Raman spectroscopy.Chemical science · 2019Article
- Precision Risk Analysis of Cancer Therapy with Interactive Nomograms and Survival Plots.IEEE transactions on visualization and computer graphics · 2019Article
- Analysis of oncogenic activities of protein kinase D1 in head and neck squamous cell carcinoma.BMC cancer · 2018Article
- Autoregulation of RANK ligand in oral squamous cell carcinoma tumor cells.Journal of cellular physiology · 2018Article
- Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model.Oncotarget · 2017Article
- Synergistic anti-cancer effects of epigenetic drugs on medulloblastoma cells.Cellular oncology (Dordrecht, Netherlands) · 2017Article
- Metabolic Imaging of Head and Neck Cancer Organoids.PloS one · 2017Article
- Spheroid Culture of Head and Neck Cancer Cells Reveals an Important Role of EGFR Signalling in Anchorage Independent Survival.PloS one · 2016Article
- In Vivo Autofluorescence Imaging of Tumor Heterogeneity in Response to Treatment.Neoplasia (New York, N.Y.) · 2015Article
- ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.Oncotarget · 2015Article
- Proton radiobiology.Cancers · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic management of locally advanced, recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is often limited by a rather unfavorable efficacy and toxicity ratio. Since the 1990s, targeted molecular therapy has been extensively investigated both as a single modality and in combination with cytotoxic treatments, such as radiotherapy or chemotherapy. EGFR is commonly over expressed in HNSCC and is an attractive molecular target. The EGFR signaling pathway is involved in a variety of cellular responses including cell growth and proliferation, and monoclonal antibodies and small-molecule inhibitors have been developed to inhibit EGFR pathways. Agents that target angiogenesis have also been tested in combination with EGFR inhibitors. A number of phase I/II and phase III studies have demonstrated that patients with high-risk HNSCC or those receiving palliative treatment for recurrent or metastatic disease benefit from the addition of EGFR inhibitors to chemotherapy and radiotherapy. This Review discusses the rationale for using targeted therapies based on inhibition of EGFR and angiogenesis, and describes the most recent preclinical and clinical evidence of the important role for targeted therapies in the management of head and neck cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.